{"id":"iv-amiodarone","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypotension"},{"rate":"3-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Phlebitis at injection site"},{"rate":"3-8","effect":"Nausea"},{"rate":"1-5","effect":"Pulmonary toxicity (chronic use)"},{"rate":"2-10","effect":"Thyroid dysfunction (chronic use)"},{"rate":"1-3","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amiodarone is a Class III antiarrhythmic agent that primarily blocks potassium channels and prolongs the action potential duration and refractory period. It also has properties of Classes I, II, and IV antiarrhythmics, blocking sodium and calcium channels and beta-adrenergic receptors, making it a broad-spectrum antiarrhythmic effective for both atrial and ventricular arrhythmias.","oneSentence":"Amiodarone blocks cardiac potassium, sodium, calcium, and beta-adrenergic channels to slow electrical conduction and suppress arrhythmias.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:31.100Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation with rapid ventricular response"},{"name":"Ventricular tachycardia"},{"name":"Ventricular fibrillation"},{"name":"Supraventricular tachycardia refractory to other agents"}]},"trialDetails":[{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT03868150","phase":"PHASE4","title":"Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment","status":"RECRUITING","sponsor":"Stanford University","startDate":"2017-03-01","conditions":"Postoperative Atrial Fibrillation","enrollment":600},{"nctId":"NCT04844801","phase":"NA","title":"Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-11-09","conditions":"Supraventricular Arrhythmia, Septic Shock","enrollment":240},{"nctId":"NCT04704050","phase":"PHASE4","title":"Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence","status":"TERMINATED","sponsor":"Tulane University School of Medicine","startDate":"2021-05-15","conditions":"Atrial Fibrillation, Atrial Fibrillation Recurrent","enrollment":22},{"nctId":"NCT06067438","phase":"PHASE2","title":"Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-06-21","conditions":"Atrial Fibrillation, Esophageal Carcinoma","enrollment":90},{"nctId":"NCT02750319","phase":"PHASE3","title":"Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-04","conditions":"Thoracic Surgery, Atrial Fibrillation in High Risk Patients","enrollment":184},{"nctId":"NCT06262932","phase":"PHASE4","title":"Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response","status":"COMPLETED","sponsor":"Police General Hospital, Thailand","startDate":"2024-05-01","conditions":"Atrial Fibrillation","enrollment":24},{"nctId":"NCT06632925","phase":"","title":"Utility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Software: a Prospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2024-10-01","conditions":"Atrial Fibrillation (AF)","enrollment":80},{"nctId":"NCT05169866","phase":"PHASE3","title":"Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2022-05-29","conditions":"New Onset Atrial Fibrillation, Complications; Cardiac, Postoperative","enrollment":274},{"nctId":"NCT04748991","phase":"PHASE3","title":"Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2024-09","conditions":"Atrial Fibrillation, Post-cardiac Surgery","enrollment":50},{"nctId":"NCT05287191","phase":"PHASE3","title":"MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-01-05","conditions":"Atrial Fibrillation New Onset","enrollment":200},{"nctId":"NCT04168970","phase":"","title":"Percutaneous Left Stellate Ganglion Block In Out-of-hospital Cardiac Arrest Due to Refractory VEntricular Arrhythmias (LIVE Study)","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2019-07-15","conditions":"Out-Of-Hospital Cardiac Arrest, Ventricular Fibrillation Sustained","enrollment":53},{"nctId":"NCT06125925","phase":"NA","title":"Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-11-06","conditions":"Atrial Fibrillation, HFpEF - Heart Failure With Preserved Ejection Fraction","enrollment":436},{"nctId":"NCT05004077","phase":"PHASE4","title":"Repeated Amiodarone Dosing In Cardiac surgicaL Procedures","status":"TERMINATED","sponsor":"Kevin W Hatton, MD, PhD","startDate":"2021-11-02","conditions":"Atrial Fibrillation","enrollment":3},{"nctId":"NCT05993897","phase":"NA","title":"Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling","status":"UNKNOWN","sponsor":"Aswan University","startDate":"2023-08","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT04234906","phase":"PHASE4","title":"Prevention of Post-Operative Cardiac Arrhythmias","status":"UNKNOWN","sponsor":"Jeffrey Moak","startDate":"2023-01","conditions":"Cardiac; Dysrhythmia, Postoperative, Congenital Heart Surgery","enrollment":870},{"nctId":"NCT04092621","phase":"PHASE4","title":"Rapid Atrial Fibrillation Treatment Strategy","status":"UNKNOWN","sponsor":"Our Lady of the Lake Hospital","startDate":"2019-09-16","conditions":"New Onset Atrial Fibrillation, Sepsis, Respiratory Failure","enrollment":40},{"nctId":"NCT02668432","phase":"PHASE4","title":"Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock","status":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-05","conditions":"New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock","enrollment":9},{"nctId":"NCT03734562","phase":"NA","title":"Trial to Evaluate the Efficacy and Safety of Substrate Ablation of Monomorphic Ventricular Tachycardia","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2010-07","conditions":"Monomorphic Ventricular Tachycardia","enrollment":180},{"nctId":"NCT02132767","phase":"PHASE3","title":"Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-05","conditions":"Postoperative Atrial Fibrillation","enrollment":523},{"nctId":"NCT00739193","phase":"PHASE2","title":"A Randomized, Placebo-Controlled, Double-Blind, Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure","status":"WITHDRAWN","sponsor":"Prism Pharmaceuticals","startDate":"2008-08","conditions":"Blood Pressure","enrollment":""},{"nctId":"NCT00420953","phase":"PHASE1","title":"Relative Bioavailability of PM101 IV and Cordarone IV","status":"COMPLETED","sponsor":"Prism Pharmaceuticals","startDate":"2006-12-18","conditions":"Healthy","enrollment":""},{"nctId":"NCT02025465","phase":"PHASE4","title":"Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control","status":"UNKNOWN","sponsor":"CAMC Health System","startDate":"2013-12","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":150},{"nctId":"NCT01558128","phase":"NA","title":"Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2012-03","conditions":"Cardiac Disease","enrollment":1},{"nctId":"NCT01401647","phase":"PHASE3","title":"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-05","conditions":"Cardiac Arrest","enrollment":3024},{"nctId":"NCT00383799","phase":"PHASE4","title":"Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia","status":"TERMINATED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2005-09","conditions":"Ventricular Tachycardia, Wide QRS Tachycardia","enrollment":302},{"nctId":"NCT00121524","phase":"PHASE2","title":"Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome","status":"COMPLETED","sponsor":"Petter Andreas Steen","startDate":"2003-01","conditions":"Cardiac Arrest","enrollment":904},{"nctId":"NCT01026090","phase":"PHASE4","title":"Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2009-11","conditions":"Atrial Fibrillation","enrollment":292},{"nctId":"NCT01627106","phase":"PHASE4","title":"A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)","status":"WITHDRAWN","sponsor":"Advanz Pharma","startDate":"2012-09","conditions":"Atrial Fibrillation","enrollment":""},{"nctId":"NCT01817439","phase":"PHASE3","title":"Safety and Efficacy of Oral Versus Intravenous Amiodarone in the Treatment of AF","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2013-05","conditions":"Atrial Fibrillation","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"iv Amiodarone","genericName":"iv Amiodarone","companyName":"Hospital General Universitario Gregorio Marañon","companyId":"hospital-general-universitario-gregorio-mara-on","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amiodarone is a small molecule that blocks the HERG channel, a voltage-gated inwardly rectifying potassium channel KCNH2, classified as a blocker. It is used to treat conditions such as atrial fibrillation, atrial flutter, and heart failure with preserved ejection fraction, as seen in clinical trials on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}